Mometasone furoate

also known as MFNS · Nasonex · mometasone furoate monohydrate · mometasone · Elocon · MMF · Mometasone Furoate Nasal Spray · SCH 32088 · +6 more

Other / unclassified

Developed for: asthma · seasonal allergic rhinitis · allergic rhinitis · chronic rhinosinusitis · perennial allergic rhinitis · nasal cavity polyp · adenoid hypertrophy · obstructive sleep apnea syndrome
+26 more
· psoriasis · radiodermatitis · childhood onset asthma · chronic obstructive pulmonary disease · eosinophilic esophagitis · hyperpigmentation of the skin · nasal disorder · polyp of ethmoidal sinus · sinusitis · Achoo syndrome · alopecia areata · anosmia · atopic eczema · chronic ethmoidal sinusitis · enuresis · rhinitis · sickle cell disease · spinal cord injury · otitis externa · otitis media with effusion · paronychia · pharyngitis · phimosis · vasomotor rhinitis · vitiligo · vulvar lichen sclerosus
Investigated by: Organon and Co · Novartis · Intersect ENT · Lyra Therapeutics · Novartis Pharmaceuticals · Schering-Plough
+55 more
· GlaxoSmithKline · Glenmark Specialty S.A. · LEO Pharma · National Heart, Lung, and Blood Institute (NHLBI) · Sandoz · Zalicus · Amneal Pharmaceuticals, LLC · Assiut University · Benha University · Bioskin GmbH · California Allergy and Asthma Medical Group, Inc. · Children's Hospital Medical Center, Cincinnati · Children´s Clinic, Randers · Collin County Ear Nose & Throat · Creighton University · Dr. Behcet Uz Children's Hospital · EsoCap AG · FGK Clinical Research GmbH · FGK Representative Service B.V. · First Affiliated Hospital, Sun Yat-Sen University · Hvidovre University Hospital · Indonesia University · Integrated Therapeutics Group · Istanbul Training and Research Hospital · James J. Peters Veterans Affairs Medical Center · Javelin Pharmaceuticals · Jeffrey Glassberg · Kessler Institute for Rehabilitation · Liaquat University of Medical & Health Sciences · MEDA Pharma GmbH & Co. KG · Massachusetts Eye and Ear Infirmary · Massachusetts General Hospital · Meda Pharmaceuticals · Merck Sharp & Dohme LLC · Mogens Bove · Monash Health · Montefiore Medical Center · Morten Hostrup, PhD · Murdoch Childrens Research Institute · National Cancer Institute (NCI) · North Central Cancer Treatment Group · Novum Pharmaceutical Research Services · PH&T S.p.A. · Royal Children's Hospital · Sameh Sarsik · Silesian University of Medicine · Tongji Hospital · University Hospital, Ghent · University of Alberta · University of Arizona · University of Urbino "Carlo Bo" · Vastra Gotaland Region · Washington University School of Medicine · Yao Liao · Yingu Pharmaceutical Co., Ltd

Regulatory milestones approvals, filings & regulatory actions · 16 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed asthma 1 milestone
Filed	EU (EMA)	—	asthma	—	“The regulatory submissions for IND/MF and IND/GLY/MF have recently been accepted for review by the European Medicines Agency (EMA).” novartis.com ↗
Filed chronic obstructive pulmonary disease 1 milestone
Filed	US (FDA)	DULERA	chronic obstructive pulmonary disease	2011-07-29	“DULERA (mometasone furoate and formoterol fumarate dihydrate) for the treatment of chronic obstructive pulmonary disease (COPD) has been accepted for review by the FDA.” merck.com ↗
Approved Indication not stated 7 milestones
Approved	EU (EMA)	Atectura Breezhaler	—	2020-05-30	europa.eu ↗
Label expansion	US (FDA)	SINUVA	—	2020-04-28	fda.gov ↗
Label expansions (2)	US (FDA)	ASMANEX HFA	—	2016-07-12 – 2019-08-12	fda.gov ↗
Label expansions (3)	US (FDA)	ELOCON	—	1995-10-03 – 2013-04-19	fda.gov ↗
Label expansions (5)	US (FDA)	NASONEX	—	1998-11-18 – 2011-01-19	fda.gov ↗
Label expansion	US (FDA)	ASMANEX TWISTHALER	—	2008-02-01	fda.gov ↗
Approved	US (FDA)	ELOCON	—	1987-04-30	fda.gov ↗

Trials 105 · started per year

today

US approved 1987

EU approved 2020

198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT05887843	Jun → Sep 2023	seasonal allergic rhinitis	Sandoz	Terminated	No outcome recorded Stop: Business
Phase 1	NCT02967731	Jun → Dec 2017	chronic rhinosinusitis	Lyra Therapeutics	Completed	No outcome recorded
Phase 1	NCT02973776	Dec 2016 → Feb 2017	psoriasis	LEO Pharma	Completed	No outcome recorded
Phase 1	NCT01353599	Aug 2011 → Mar 2016	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Unknown	No outcome recorded
Phase 1	NCT00662883	Nov 2007 → Feb 2008	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00544687	Sep → Nov 2007	—	Zalicus	Completed	No outcome recorded
Phase 1	NCT00418509	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 217 trials · 3 met primary · 1 missed
Phase 2	NCT06126952	Oct 2023 → Feb 2024	seasonal allergic rhinitis	MEDA Pharma GmbH & Co. KG	Completed	No outcome recorded
Phase 2	NCT05505214	Sep 2023 → Sep 2025	radiodermatitis	Montefiore Medical Center	Withdrawn	No outcome recorded
Phase 2	NCT05035654	Nov 2021 → Aug 2023	chronic rhinosinusitis	Lyra Therapeutics	Completed	No outcome recorded
Phase 2	NCT04849390	Jun 2021 → Oct 2023	eosinophilic esophagitis	EsoCap AG	Completed	Met primary
Phase 2	NCT04589663	Jun 2021 → Apr 2022	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT04041609	May 2019 → Mar 2020	chronic rhinosinusitis	Lyra Therapeutics	Completed	Missed primary
Phase 2	NCT04179461	Mar 2018 → Oct 2019	childhood onset asthma	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT02113267	Apr 2014 → Sep 2018	eosinophilic esophagitis	Mogens Bove	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02061202	Mar 2014 → Nov 2017	sickle cell disease	Jeffrey Glassberg	Completed	No outcome recorded
Phase 2	NCT01894503	Jun → Oct 2013	chronic rhinosinusitis	Intersect ENT	Completed	No outcome recorded
Phase 2	NCT01615874	Jan → Sep 2013	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 2	NCT01555151	Jul 2012 → Jul 2013	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01502371	Jan 2012 → Jan 2015	asthma	Organon and Co	Completed	Met primary
Phase 2	NCT00845481	Jan → Mar 2009	psoriasis	LEO Pharma	Completed	No outcome recorded
Phase 2	NCT00635882	Feb 2008 → Jun 2009	asthma	Organon and Co	Completed	Met primary
Phase 2	NCT00557739	Nov 2007 → Jan 2008	psoriasis	Zalicus	Completed	No outcome recorded
Phase 2	NCT00779545	Apr → Aug 2004	perennial allergic rhinitis	Organon and Co	Completed	No outcome recorded

Phase 2/31 trial · 1 missed
Phase 2/3	NCT01732536	Jan → Nov 2013	chronic rhinosinusitis, nasal cavity polyp	Intersect ENT	Completed	Missed primary
Phase 345 trials · 21 met primary · 8 missed
Phase 3	NCT05776927	Aug 2026 → Dec 2028 expected	asthma	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT05295459	May 2022 → Apr 2025	chronic rhinosinusitis	Lyra Therapeutics	Completed	No outcome recorded
Phase 3	NCT05219968	Jan 2022 → Mar 2024	chronic rhinosinusitis	Lyra Therapeutics	Completed	Missed primary
Phase 3	NCT04484493	Aug → Oct 2020	COVID-19, anosmia	Benha University	Completed	Missed primary
Phase 3	NCT03358329	Nov 2017 → Jan 2019	chronic rhinosinusitis, polyp of ethmoidal sinus	Intersect ENT	Completed	No outcome recorded
Phase 3	NCT02892344	Jan 2017 → Nov 2018	asthma	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT02870205	Aug 2016 → Jan 2017	seasonal allergic rhinitis	Glenmark Specialty S.A.	Completed	Met primary
Phase 3	NCT02741271	May 2016 → Dec 2017	asthma	Organon and Co	Completed	Met primary
Phase 3	NCT02631551	Mar → Jul 2016	seasonal allergic rhinitis	Glenmark Specialty S.A.	Completed	Met primary
Phase 3	NCT02571777	Dec 2015 → Jun 2019	asthma	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT02291549	Dec 2014 → Oct 2016	chronic rhinosinusitis, polyp of ethmoidal sinus	Intersect ENT	Completed	Met primary
Phase 3	NCT02125253	Jan → Mar 2014	seasonal allergic rhinitis	Amneal Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 3	NCT01702103	Oct 2012 → Jan 2013	Achoo syndrome, nasal disorder	PH&T S.p.A.	Unknown	No outcome recorded
Phase 3	NCT01386125	Jun 2011 → Feb 2013	nasal cavity polyp	Organon and Co	Completed	Met primary
Phase 3	NCT01135134	Jun → Oct 2010	perennial allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT01165424	Apr → Dec 2010	perennial allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT01038427	Dec 2009 → Feb 2010	seasonal allergic rhinitis	Sandoz	Completed	No outcome recorded
Phase 3	NCT00732381	Aug → Nov 2008	seasonal allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT00728416	Aug → Oct 2008	allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT00733005	Jul → Oct 2008	allergic rhinitis	Organon and Co	Completed	Missed primary
Phase 3	NCT00599027	May 2008 → May 2009	allergic rhinitis, asthma	Organon and Co	Completed	Met primary
Phase 3	NCT00552032	Aug 2007 → Jan 2010	adenoid hypertrophy	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00438659	Aug 2007 → Jan 2010	breast cancer, radiodermatitis, toxic dermatosis	North Central Cancer Treatment Group	Completed	Missed primary
Phase 3	NCT00442117	Jun 2007 → Jul 2009	asthma	Organon and Co	Completed	Missed primary
Phase 3	NCT00424008	Apr 2007 → Nov 2008	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00453063	Mar → Jun 2007	seasonal allergic rhinitis	Organon and Co	Completed	Mixed
Phase 3	NCT00468312	Mar → Jul 2007	seasonal allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT00720382	Mar 2007 → Jun 2008	perennial allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00423176	Dec 2006 → Jun 2008	sinusitis	Organon and Co	Terminated	Missed primary Stop: Business
Phase 3	NCT00383435	Oct 2006 → Jul 2010	chronic obstructive pulmonary disease	Organon and Co	Completed	Met primary
Phase 3	NCT00383240	Sep 2006 → Sep 2008	asthma	Organon and Co	Completed	Met primary
Phase 3	NCT00383552	Sep 2006 → Aug 2008	asthma	Organon and Co	Completed	Met primary
Phase 3	NCT00383721	Sep 2006 → Jul 2010	chronic obstructive pulmonary disease	Organon and Co	Completed	Mixed
Phase 3	NCT00381485	Jul 2006 → Jan 2008	asthma	Organon and Co	Completed	Met primary
Phase 3	NCT00378378	Jul 2006 → Jun 2008	nasal cavity polyp	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00379288	Jun 2006 → Nov 2007	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00224523	Sep 2005 → Feb 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00783224	Sep → Nov 2005	perennial allergic rhinitis	Organon and Co	Completed	Missed primary
Phase 3	NCT00732368	May 2005 → Jan 2006	perennial allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00731185	Sep 2003 → Sep 2005	nasal cavity polyp	Organon and Co	Completed	Met primary
Phase 3	NCT03879772	Mar → Jul 1996	seasonal allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT03855228	Mar → Aug 1995	allergic rhinitis	Organon and Co	Completed	Missed primary
Phase 3	NCT03882047	Aug → Sep 1994	seasonal allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT03861559	Mar → Jun 1994	seasonal allergic rhinitis	Organon and Co	Completed	Met primary
Phase 3	NCT03855189	Aug → Oct 1993	seasonal allergic rhinitis	Organon and Co	Completed	Met primary

Phase 430 trials · 2 met primary · 6 missed
Phase 4	NCT07696806	Jul 2026 → Jun 2027 expected	hyperpigmentation of the skin	Sameh Sarsik	Enrolling by invitation	No outcome recorded
Phase 4	NCT07593898	Jan 2025 → Jan 2026	allergic rhinitis	Dr. Behcet Uz Children's Hospital	Completed	No outcome recorded
Phase 4	NCT06399783	Oct 2024 → Oct 2027 expected	alopecia areata	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT05382494	Dec 2022 → Jul 2025	obstructive sleep apnea syndrome, otorhinolaryngologic disease	Murdoch Childrens Research Institute	Completed	Missed primary
Phase 4	NCT03141424	Jun 2022 → Oct 2024	asthma	Hvidovre University Hospital	Completed	No outcome recorded
Phase 4	NCT05038202	Jun 2021 → Apr 2024	allergic rhinitis	Yingu Pharmaceutical Co., Ltd	Unknown	Met primary
Phase 4	NCT04898764	Oct 2020 → Apr 2025	rhinitis	University Hospital, Ghent	Completed	No outcome recorded
Phase 4	NCT03705793	Jan 2019 → Feb 2020	allergic rhinitis, chronic rhinosinusitis	Washington University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02668302	Nov 2015 → Nov 2016	chronic ethmoidal sinusitis	Collin County Ear Nose & Throat	Completed	Missed primary
Phase 4	NCT02397915	Mar → Jun 2015	allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT02495064	Jan 2015 → Dec 2016	radiodermatitis	Yao Liao	Unknown	No outcome recorded
Phase 4	NCT01997463	Aug 2014 → Jun 2016	childhood onset asthma	University of Arizona	Completed	Missed primary
Phase 4	NCT02110654	Jun 2014 → Nov 2020	asthma, nasal cavity polyp, sinusitis	First Affiliated Hospital, Sun Yat-Sen University	Completed	No outcome recorded
Phase 4	NCT02565212	May → Oct 2014	allergic rhinitis	Istanbul Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT01616160	Jul 2013 → Jan 2017	nasal cavity polyp	Massachusetts General Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01861145	May 2013 → Dec 2015	enuresis, obstructive sleep apnea syndrome	University of Alberta	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01471340	Jan 2012 → Nov 2016	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01635088	Jun → Dec 2011	asthma	California Allergy and Asthma Medical Group, Inc.	Completed	No outcome recorded
Phase 4	NCT01098071	Aug 2008 → Sep 2009	adenoid hypertrophy	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00521599	May 2007 → Mar 2009	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00491504	Feb → Jul 2007	seasonal allergic rhinitis	Organon and Co	Completed	Missed primary
Phase 4	NCT00687531	Nov 2006 → Sep 2009	asthma	Organon and Co	Terminated	No outcome recorded
Phase 4	NCT00394355	Sep 2006 → Oct 2009	asthma	Organon and Co	Completed	Missed primary
Phase 4	NCT00491374	Sep 2006 → Oct 2007	perennial allergic rhinitis	Schering-Plough	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00359216	May 2006 → Jan 2008	obstructive sleep apnea syndrome, perennial allergic rhinitis	Organon and Co	Completed	Missed primary
Phase 4	NCT00358527	May → Oct 2006	seasonal allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00553891	May 2006 → Oct 2009	adenoid hypertrophy, nasal disorder	Organon and Co	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00711165	Aug 2005 → Apr 2006	asthma	Creighton University	Completed	No outcome recorded
Phase 4	NCT00236106	Feb → Jun 2005	atopic eczema	Children´s Clinic, Randers	Completed	No outcome recorded
Phase 4	NCT00834119	Sep 2003 → Apr 2004	allergic rhinitis	Organon and Co	Completed	No outcome recorded

Phase not applicable5 trials
—	NCT07800273	Sep 2026 → May 2027 expected	chronic rhinosinusitis	Liaquat University of Medical & Health Sciences	Not yet recruiting	No outcome recorded
—	NCT07527260	Apr 2026 → Apr 2027 expected	allergic rhinitis	Tongji Hospital	Not yet recruiting	No outcome recorded
—	NCT06780644	Feb → May 2025 overdue	hyperpigmentation of the skin	Indonesia University	Not yet recruiting	No outcome recorded
—	NCT06077019	Oct 2023 → Jul 2026 overdue	—	Morten Hostrup, PhD	Recruiting	No outcome recorded
—	NCT07777796	Jul 2022 → Jul 2026	chronic rhinitis	Silesian University of Medicine	Completed	No outcome recorded
Comparator or background therapy67 trials
Phase 0	NCT07016763 Comparator	Sep 2024 → Mar 2025	allergic rhinitis	Isola Tiberina - Gemelli Isola Hospital, Rome, Italy	Completed	No outcome recorded
Phase 0	NCT05293119 Comparator	May 2022 → May 2023	vitiligo	Pi Research Consultancy Center, Bangladesh	Unknown	No outcome recorded
Phase 0	NCT05017454 Comparator	May 2021 → Jan 2023	alopecia areata	Kasr El Aini Hospital	Completed	No outcome recorded
Phase 0	NCT03491098 Comparator	May 2018 → Apr 2019	otitis media with effusion	Muteea Mubark Salmen Bakuwiri	Unknown	No outcome recorded
Phase 1	NCT02588326 Comparator	Sep 2018 → Jul 2020	hypersensitivity reaction disease	University of Florida	Completed	No outcome recorded
Phase 1	NCT02109185 Comparator	Sep → Oct 2013	seasonal allergic rhinitis	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1/2	NCT01523236 Comparator	Dec 2011 → Jan 2012	seasonal allergic rhinitis	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 2	NCT07016113 Comparator	Jul → Oct 2025 overdue	vitiligo	Padjadjaran University	Not yet recruiting	No outcome recorded
Phase 2	NCT06914908 Background	May 2025 → Jan 2031 expected	chronic rhinosinusitis	Sanofi	Enrolling by invitation	No outcome recorded
Phase 2	NCT06691113 Background	Dec 2024 → Mar 2026 overdue	chronic rhinosinusitis	Sanofi	Active not recruiting	No outcome recorded
Phase 2	NCT06013241 Background	Oct 2023 → Sep 2025	chronic rhinosinusitis	Insmed Incorporated	Completed	Missed primary
Phase 2	NCT04499235 Background	Jan 2020 → Mar 2021	bullous pemphigoid	Alkahest, Inc.	Terminated	No outcome recorded
Phase 2	NCT03614923 Background	Nov 2018 → Sep 2020	chronic rhinosinusitis	AnaptysBio, Inc.	Completed	Missed primary
Phase 2	NCT04532736 Comparator	Sep 2017 → Mar 2019	nasal cavity polyp	Dokuz Eylul University	Completed	No outcome recorded
Phase 2	NCT02874144 Background	Jun 2016 → Jan 2020	nasal cavity polyp	Northwestern University	Completed	No outcome recorded
Phase 2	NCT02573233 Background	Jan 2016 → Jan 2018	asthma	Sanofi	Completed	Mixed
Phase 2	NCT01609478 Background	Aug 2012 → Jul 2013	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01119313 Comparator	Feb → Mar 2010	atopic eczema	Almirall, S.A.	Completed	No outcome recorded
Phase 2	NCT00784732 Comparator	Sep → Dec 2008	seasonal allergic rhinitis	Novartis	Completed	No outcome recorded
Phase 2	NCT00552110 Comparator	Jul 2007 → Feb 2008	seasonal allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 2	NCT01228656 Comparator	Sep 2006 → Oct 2010	psoriasis	Azidus Brasil	Suspended	No outcome recorded
Phase 2	NCT00750750 Comparator	Jan → Sep 2003	sinusitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT06834347 Background	Feb 2025 → Oct 2026 expected	chronic rhinosinusitis	Sanofi	Active not recruiting	No outcome recorded
Phase 3	NCT06834360 Background	Feb 2025 → Nov 2026 expected	chronic rhinosinusitis	Sanofi	Active not recruiting	No outcome recorded
Phase 3	NCT07311759 Comparator	Aug 2024 → Dec 2025 overdue	paronychia	Cairo University	Active not recruiting	No outcome recorded
Phase 3	NCT05545072 Background	Oct 2023 → Jul 2024	chronic rhinosinusitis	Emory University	Terminated	No outcome recorded Stop: Business
Phase 3	NCT04670653 Comparator	Aug 2022 → Jul 2023	allergic rhinitis	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT05390255 Background	May 2022 → Dec 2024	sinusitis	Beijing Tongren Hospital	Unknown	No outcome recorded
Phase 3	NCT04851964 Background	Apr 2021 → Sep 2024	chronic rhinosinusitis	AstraZeneca	Completed	Met primary
Phase 3	NCT03401229 Comparator	Jan 2018 → Jul 2020	nasal cavity polyp	AstraZeneca	Completed	Met primary
Phase 3	NCT03085797 Background	May 2017 → Dec 2019	nasal cavity polyp	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02912468 Background	Dec 2016 → Jul 2018	chronic rhinosinusitis	Sanofi	Completed	Met primary
Phase 3	NCT02898454 Background	Nov 2016 → Aug 2018	chronic rhinosinusitis	Sanofi	Completed	Met primary
Phase 3	NCT02554786 Comparator	Dec 2015 → Nov 2018	asthma	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT02478398 Background	Jul 2015 → Nov 2018	seasonal allergic rhinitis	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 3	NCT02498509 Comparator	May 2015 → Mar 2016	perennial allergic rhinitis	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01700192 Background	Jan 2013 → Apr 2015	perennial allergic rhinitis	ALK-Abelló A/S	Completed	Met primary
Phase 3	NCT01026870 Comparator	Jun 2012 → Dec 2013	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 3	NCT01372865 Comparator	Jun 2012 → Feb 2013	allergic rhinitis	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT01671852 Comparator	May 2012 → Jul 2015	obstructive sleep apnea syndrome	Children's & Women's Health Centre of British Columbia	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT01470053 Comparator	Mar → Dec 2011	perennial allergic rhinitis	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT00604500 Background	Mar → Nov 2008	asthma, chronic obstructive pulmonary disease	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00550550 Background	Nov 2007 → Sep 2009	allergic rhinitis, conjunctivitis	ALK-Abelló A/S	Completed	Met primary
Phase 3	NCT00779740 Comparator	Feb → Apr 2005	perennial allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00751075 Comparator	Dec 2003 → May 2004	sinusitis	Organon and Co	Completed	No outcome recorded
Phase 4	NCT07532993 Comparator	Sep 2026 → Feb 2027 expected	allergic rhinitis	Liaquat National Hospital & Medical College	Not yet recruiting	No outcome recorded
Phase 4	NCT06801353 Background	Feb → Dec 2025 overdue	chronic rhinosinusitis	Beijing Tongren Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT05578482 Comparator	Oct 2022 → May 2023	atopic eczema	Jacob Pontoppidan Thyssen	Unknown	No outcome recorded
Phase 4	NCT04596189 Background	May 2021 → Apr 2024	chronic rhinosinusitis	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 4	NCT04271007 Comparator	Nov 2020 → Jul 2023	atopic eczema	Libbs Farmacêutica LTDA	Completed	No outcome recorded
Phase 4	NCT05040828 Background	Jul → Sep 2020	seasonal allergic rhinitis	Beijing Tongren Hospital	Completed	No outcome recorded
Phase 4	NCT02557269 Background	May → Oct 2015	seasonal allergic rhinitis	Association Asthma, Bulgaria	Unknown	No outcome recorded
Phase 4	NCT02559440 Comparator	Feb 2014 → Feb 2015	adenoid hypertrophy	Guangzhou Women and Children's Medical Center	Completed	No outcome recorded
Phase 4	NCT01082393 Comparator	Feb 2010 → Sep 2015	vitiligo	University Hospital, Ghent	Completed	No outcome recorded
Phase 4	NCT01333410 Comparator	Jun 2009 → Jun 2013	vitiligo	Mahidol University	Unknown	No outcome recorded
Phase 4	NCT01108198 Comparator	Oct 2006 → Jun 2011	phimosis	University of Oulu	Unknown	No outcome recorded
Phase 4	NCT00817050 Comparator	Dec 2004 → Jan 2005	allergic rhinitis	Organon and Co	Completed	No outcome recorded
—	NCT07525505 Comparator	Jan → Jun 2026 overdue	atopic eczema, otitis externa	Bezmialem Vakif University	Recruiting	No outcome recorded
—	NCT07114107 Background	Aug 2025 → Mar 2026 overdue	allergic asthma, allergic rhinitis	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
—	NCT05919316 Comparator	Jul 2023 → Oct 2024	allergic rhinitis	National University of Malaysia	Completed	No outcome recorded
—	NCT05912192 Comparator	Feb 2022 → Apr 2023	allergic rhinitis	National University of Malaysia	Completed	No outcome recorded
—	NCT05228483 Comparator	Nov 2021 → Nov 2023	vulvar lichen sclerosus	Xijing Hospital	Unknown	No outcome recorded
—	NCT05348148 Comparator	Jun 2020 → Mar 2032 expected	vasomotor rhinitis	Camillians Saint Mary's Hospital Luodong	Recruiting	No outcome recorded
—	NCT04085744 Comparator	Nov 2019 → Jun 2020	pharyngitis	Derince Training and Research Hospital	Completed	No outcome recorded
—	NCT03451318 Comparator	Mar 2018 → May 2019	obstructive sleep apnea syndrome	Shanghai Stomotological Hospital	Unknown	No outcome recorded
—	NCT00967967 Background	Mar 2009 → Jun 2014	allergic rhinitis, asthma	Laval University	Suspended	No outcome recorded
—	NCT00618332 Comparator	Apr → Jul 2008	seasonal allergic rhinitis	University of Chicago	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 42

Date	Issuer	Release
2026-07-21	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years glenmarkpharma.com ↗ With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.
2025-11-10	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership glenmarkpharma.com ↗ Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS® Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children – specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adult s and pediatric patients 12 years of age and older.
2025-06-02	Lyra Therapeutics	Results Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) lyratherapeutics.com ↗ ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)
2025-05-07	Lyra Therapeutics	Results Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 lyratherapeutics.com ↗ Repeat LYR-210 treatment demonstrated a favorable safety profile, similar to that observed in the Primary Study Stage in patients with CRS.
2024-11-12	Lyra Therapeutics	Results Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update lyratherapeutics.com ↗ Safety data for LYR-210 was generally consistent with the 24-week primary treatment phase, including for those patients that received a repeat dosing, resulting in a 12-month treatment period.
2024-08-14	Lyra Therapeutics	Results Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update lyratherapeutics.com ↗ In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps
2024-05-06	Lyra Therapeutics	Results Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis lyratherapeutics.com ↗ ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks.
2023-11-07	Lyra Therapeutics	Results Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update lyratherapeutics.com ↗ Data evaluating computed tomography (CT) scans, a pre-specified secondary endpoint, demonstrated statistically significant improvement in ethmoid sinus opacification in patients who received LYR-220, compared to sham control at week 24 (p=0.035).
2023-09-12	Lyra Therapeutics	Results Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery lyratherapeutics.com ↗ Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.
2023-07-03	Impax Laboratories, LLC	Regulatory Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter amneal.com ↗ In addition, the Company announced it has received Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (“FDA”) for five complex generics products.
2022-09-23	Glenmark Pharmaceuticals Ltd. India	Regulatory Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada glenmarkpharma.com ↗ RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal sp ray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
2022-09-10	Lyra Therapeutics	Results Lyra Therapeutics Announces Additional Data Presentations from Phase 2 LANTERN Study at the American Rhinologic Society Annual Meeting lyratherapeutics.com ↗ Compared to control, significantly higher proportions of LYR-210-treated subjects improved from moderate or severe at baseline to mild or none at week 24 in nasal blockage, nasal discharge, and facial pain/pressure (p<0.05).
2022-04-29	Lyra Therapeutics	Results Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022 lyratherapeutics.com ↗ In the LANTERN Phase 2 study, LYR-210 (7500 µg) demonstrated rapid, clinically meaningful and durable symptom improvement in a composite score of CRS cardinal symptoms over six months.
2022-03-17	Perrigo Company	Regulatory PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY perrigo.com ↗ Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg).
2021-11-09	Lyra Therapeutics	Results Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update lyratherapeutics.com ↗ The recently completed pharmacokinetic (PK) study showed that Mometasone Furoate (MF) blood levels were constant over the 56 days, providing further evidence that LYR-210 delivers a steady daily dose of MF with accompanying rapid symptom relief during this time period.
2021-10-04	Lyra Therapeutics	Results Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society lyratherapeutics.com ↗ LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients
2021-09-30	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK glenmarkpharma.com ↗
2021-09-21	Lyra Therapeutics	Results Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology lyratherapeutics.com ↗ LYR-210 (7500 µg) was shown to be safe and well-tolerated over the 24-week treatment period and demonstrated statistically significant, rapid, durable, dose-dependent global symptom improvement based on composite Cardinal Symptoms (CS) scores and Sino-Nasal Outcome Test (SNOT-22).
2021-09-09	Lyra Therapeutics	Results Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy lyratherapeutics.com ↗ The results demonstrate that XTreo™ MF provides targeted, sustained and efficient dosing to local sinus tissues that is superior to intranasal corticosteroid sprays (INCS).
2021-09-03	Novartis Pharmaceuticals	Results Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2021-06-30	Lyra Therapeutics	Results Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis lyratherapeutics.com ↗ Data obtained from the study are supportive of LYR-210’s safety profile and provide a PK bridge to the established safety of mometasone furoate (MF) for a 505(b)(2) pathway for New Drug Approval (NDA) submission.
2021-04-26	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age glenmarkpharma.com ↗ Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
2021-04-11	Lyra Therapeutics	Results Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual lyratherapeutics.com ↗ Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achieved statistically significant improvement across 3 cardinal symptoms at week 24 in the LANTERN study
2021-02-22	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia glenmarkpharma.com ↗ Marketing approval received from the Ministry of Health of the Russian Federation
2020-12-07	Lyra Therapeutics	Results Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps lyratherapeutics.com ↗ 7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16 (p=0.021), 20 (p=0.012) and 24 (p=0.016) compared to control.
2020-09-10	Lyra Therapeutics	Results Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗ today announced the presentation of data showing that LYR-210 demonstrated a significant reduction of sinonasal Type 2 inflammation in surgically naïve patients with chronic rhinosinusitis (CRS).
2020-09-07	Novartis Pharmaceuticals	Results Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings novartis.com ↗ High-dose, once-daily Enerzair ® Breezhaler ® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks
2020-07-07	Novartis Pharmaceuticals	Regulatory Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU novartis.com ↗ European Commission approves once-daily Enerzair ® Breezhaler ® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS
2020-06-29	Novartis Pharmaceuticals	Regulatory Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2020-06-05	Novartis Pharmaceuticals	Results Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗ Once-daily Enerzair ® Breezhaler ® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma 1 .
2020-05-01	Novartis Pharmaceuticals	Regulatory Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma novartis.com ↗
2020-01-06	Lyra Therapeutics	Regulatory Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis lyratherapeutics.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LYR-210 for the treatment of chronic rhinosinusitis (CRS), a debilitating chronic disease affecting millions of patients.
2019-12-20	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia glenmarkpharma.com ↗
2019-12-06	Novartis Pharmaceuticals	Results Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy novartis.com ↗ Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate
2019-09-30	Novartis Pharmaceuticals	Results Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma novartis.com ↗ Novartis today announced that investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate or IND/MF) was superior to mometasone furoate (MF) in improving trough forced expiratory volume in one second (FEV 1 ) after 26 weeks
2019-09-30	Novartis Pharmaceuticals	Results Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma novartis.com ↗ Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2]
2019-05-09	Glenmark Pharmaceuticals Ltd. India	Results Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years glenmarkpharma.com ↗
2019-04-25	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product glenmarkpharma.com ↗
2018-08-08	Glenmark Pharmaceuticals Ltd. India	Regulatory Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis glenmarkpharma.com ↗ Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis
2017-05-22	Merck Sharp & Dohme LLC	Results Merck Announces Top-Line Results from the Long Term LABA Safety Study of DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol merck.com ↗ We are pleased this study met both its primary safety and key secondary efficacy endpoints,
2011-10-24	Merck Sharp & Dohme LLC	Results Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) merck.com ↗ In Study 2, DULERA 200 mcg/10 mcg and DULERA 400 mcg/10 mcg significantly improved AM predose FEV1 at Week 13 compared to treatment with placebo, but neither dose of DULERA reached statistical significance compared to treatment with formoterol 10 mcg.
2005-04-11	Perrigo Company	Regulatory Perrigo Company Announces FDA Approval For Mometasone Furoate Topical Solution perrigo.com ↗ The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Agis Industries subsidiary has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Mometasone Furoate Topical Solution USP, 0.1% (Lotion).

All press releases naming this drug 62 releases

Date	Issuer	Release
2026-07-21	Glenmark Pharmaceuticals Ltd. India	Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years glenmarkpharma.com ↗
2025-11-10	Glenmark Pharmaceuticals Ltd. India	Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership glenmarkpharma.com ↗
2025-10-06	Lyra Therapeutics	Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study lyratherapeutics.com ↗
2025-06-02	Lyra Therapeutics	Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) lyratherapeutics.com ↗
2025-05-07	Lyra Therapeutics	Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 lyratherapeutics.com ↗
2024-11-12	Lyra Therapeutics	Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update lyratherapeutics.com ↗
2024-10-15	Lyra Therapeutics	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗
2024-09-27	Lyra Therapeutics	Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings lyratherapeutics.com ↗
2024-08-14	Lyra Therapeutics	Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update lyratherapeutics.com ↗
2024-05-06	Lyra Therapeutics	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis lyratherapeutics.com ↗
2023-11-07	Lyra Therapeutics	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update lyratherapeutics.com ↗
2023-09-12	Lyra Therapeutics	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery lyratherapeutics.com ↗
2023-08-29	Lyra Therapeutics	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗
2023-07-03	Impax Laboratories, LLC	Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter amneal.com ↗
2023-04-25	Lyra Therapeutics	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis lyratherapeutics.com ↗
2023-02-06	Lyra Therapeutics	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients lyratherapeutics.com ↗
2022-09-23	Glenmark Pharmaceuticals Ltd. India	Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada glenmarkpharma.com ↗
2022-09-13	Lyra Therapeutics	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study lyratherapeutics.com ↗
2022-09-10	Lyra Therapeutics	Lyra Therapeutics Announces Additional Data Presentations from Phase 2 LANTERN Study at the American Rhinologic Society Annual Meeting lyratherapeutics.com ↗
2022-09-08	Lyra Therapeutics	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients lyratherapeutics.com ↗
2022-06-16	Glenmark Pharmaceuticals Ltd. India	Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India glenmarkpharma.com ↗
2022-04-29	Lyra Therapeutics	Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022 lyratherapeutics.com ↗
2022-04-25	Lyra Therapeutics	Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients lyratherapeutics.com ↗
2022-03-17	Perrigo Company	PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY perrigo.com ↗
2022-02-28	Lyra Therapeutics	Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients lyratherapeutics.com ↗
2022-01-24	Lyra Therapeutics	Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients lyratherapeutics.com ↗
2021-11-09	Lyra Therapeutics	Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update lyratherapeutics.com ↗
2021-10-19	Lyra Therapeutics	Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts lyratherapeutics.com ↗
2021-10-04	Lyra Therapeutics	Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society lyratherapeutics.com ↗
2021-09-30	Glenmark Pharmaceuticals Ltd. India	Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK glenmarkpharma.com ↗
2021-09-21	Lyra Therapeutics	Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology lyratherapeutics.com ↗
2021-09-09	Lyra Therapeutics	Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy lyratherapeutics.com ↗
2021-09-03	Novartis Pharmaceuticals	Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2021-06-30	Lyra Therapeutics	Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis lyratherapeutics.com ↗
2021-06-08	Lyra Therapeutics	Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗
2021-06-02	Lyra Therapeutics	Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets lyratherapeutics.com ↗
2021-04-26	Glenmark Pharmaceuticals Ltd. India	Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age glenmarkpharma.com ↗
2021-04-11	Lyra Therapeutics	Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual lyratherapeutics.com ↗
2021-02-22	Glenmark Pharmaceuticals Ltd. India	Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia glenmarkpharma.com ↗
2020-12-07	Lyra Therapeutics	Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps lyratherapeutics.com ↗
2020-09-10	Lyra Therapeutics	Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗
2020-09-07	Novartis Pharmaceuticals	Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings novartis.com ↗
2020-09-03	Lyra Therapeutics	Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis lyratherapeutics.com ↗
2020-07-07	Novartis Pharmaceuticals	Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU novartis.com ↗
2020-06-29	Novartis Pharmaceuticals	Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2020-06-05	Novartis Pharmaceuticals	Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗
2020-05-01	Novartis Pharmaceuticals	Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma novartis.com ↗
2020-01-06	Lyra Therapeutics	Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis lyratherapeutics.com ↗
2019-12-20	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia glenmarkpharma.com ↗
2019-12-06	Novartis Pharmaceuticals	Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy novartis.com ↗
2019-09-30	Novartis Pharmaceuticals	Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma novartis.com ↗
2019-09-30	Novartis Pharmaceuticals	Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma novartis.com ↗
2019-05-09	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years glenmarkpharma.com ↗
2019-04-25	Glenmark Pharmaceuticals Ltd. India	Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product glenmarkpharma.com ↗
2018-08-09	Perrigo Company	Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex® perrigo.com ↗
2018-08-08	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis glenmarkpharma.com ↗
2017-05-22	Merck Sharp & Dohme LLC	Merck Announces Top-Line Results from the Long Term LABA Safety Study of DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol merck.com ↗
2016-03-24	Apotex Inc.	Apotex Launches First Generic Version of Merck's Nasonex® apotex.com ↗
2012-06-15	Merck Sharp & Dohme LLC	U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit merck.com ↗
2012-04-04	Merck Sharp & Dohme LLC	Merck Statement On NASONEX® (mometasone furoate monohydrate) Patent Trial in the U.S. District Court for the District of New Jersey merck.com ↗
2011-10-24	Merck Sharp & Dohme LLC	Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) merck.com ↗
2005-04-11	Perrigo Company	Perrigo Company Announces FDA Approval For Mometasone Furoate Topical Solution perrigo.com ↗

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 179 sources stand behind the page.

Field	Value	Cited text
Known as	mometasone furoate	“Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit...” NCT06780644 ↗ 165 “Participants received modified Kligman's formula consisting of hydroquinone 4%, tretinoin 0.05%, and mometasone furoate 0.1% immediately after standardized microneedling with a...” NCT07696806 ↗ “Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis” NCT00423176 ↗ “Schools were purposively selected, matched, and randomized to receive 9 months of supervised therapy with mometasone furoate or usual care.” PMID 30118728 ↗ Aug 2018 “QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg once daily delivered via Breezhaler®” NCT05776927 ↗ “LYR-210 is a drug depot, which contains the anti-inflammatory medication mometasone furoate (MF) pre-loaded in a single use applicator.” NCT04041609 ↗ “GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).” PMID 30910440 ↗ Mar 2019 “The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).” PMID 39676687 ↗ Dec 2024 “QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device” NCT02571777 ↗ “mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.” NCT04085744 ↗ “In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses” NCT03358329 ↗ Show 155 more sources
Known as	Elocon	“Elocon® mometasone furoate 0.1% cream” NCT02973776 ↗ 1 NCT00845481 ↗
Known as	LYR-210	“LYR-210 drug matrix (mometasone furoate)” NCT05295459 ↗
Known as	LYR-220	“LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1” NCT05035654 ↗
Known as	MFNS	“This is a Phase 4 randomized, placebo-controlled, parallel-group, single-center, double-blind study to evaluate the effects of mometasone furoate nasal spray (MFNS) in subjects...” NCT00359216 ↗ 24 “A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study Of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Mild-Moderate Obstructive Sleep...” NCT00491374 ↗ “The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid...” NCT00552032 ↗ “Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis” NCT00423176 ↗ “Mometasone furoate nasal spray (MFNS), a potent intranasal corticosteroid with proved efficacy in relieving nasal allergic rhinitis symptoms” PMID 20434199 ↗ Jun 2010 “Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily.” NCT03401229 ↗ “Mometasone furoate nasal spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)” NCT00732381 ↗ “The intranasal corticosteroid mometasone furoate nasal spray (MFNS) is effective for AR symptoms including nasal congestion” PMID 23562197 ↗ Mar 2013 “mometasone furoate nasal spray (MFNS) versus amoxicillin and placebo in patients with acute, uncomplicated rhinosinusitis.” PMID 16337461 ↗ Oct 2005 “Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.” NCT00599027 ↗ “Mometasone furoate nasal spray (MFNS) has established efficacy in treating nasal allergy symptoms” PMID 21439168 ↗ Mar 2011 Show 14 more sources
Known as	MMF	“PURPOSE: A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing...” PMID 20800381 ↗ Aug 2010 1 “Mometasone furoate (MMF) 0.1% ointment” NCT05228483 ↗
Known as	mometasone	“In this double-blind study, eligible patients (≥12 years of age) with SAR were randomized 1:1:1:1 to twice-daily GSP301 (665 μg of olopatadine and 25 μg of mometasone),...” PMID 30910440 ↗ Mar 2019 2 “Mometasone is an inhaled corticosteroid (ICS), which reduces the inflammation in the airways.” NCT01471340 ↗ “Nasonex® (mometasone) versus Flonase® nasal spray” NCT00817050 ↗
Known as	Mometasone Furoate Cream	“Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid,...” NCT02495064 ↗
Known as	mometasone furoate monohydrate	“Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years” NCT00550550 ↗ 5 “Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray” NCT06126952 ↗ “Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.” NCT01700192 ↗ “Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg.” NCT02125253 ↗ NCT02109185 ↗ NCT02478398 ↗
Known as	Mometasone Furoate Nasal Spray	“Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily.” NCT03401229 ↗ 1 “Mometasone furoate nasal spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)” NCT00732381 ↗
Known as	Nasonex	“This study will hope to show that the treatment of the patient's perennial allergic rhinitis (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of...” NCT00491374 ↗ 10 “The purpose of this study is to evaluate the efficacy and safety of Nasonex® (mometasone furoate nasal spray), when used together with an antibiotic, for the relief of symptoms...” NCT00423176 ↗ “The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.” NCT00720382 ↗ “Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg.” NCT02125253 ↗ “Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD” NCT00224523 ↗ “Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray” NCT01038427 ↗ “Mometasone Furoate Nasal Spray NASONEX” NCT03451318 ↗ “Nasal Steroid (Nasonex, Flonase)” NCT02874144 ↗ NCT01861145 ↗ NCT07527260 ↗ NCT01523236 ↗
Known as	Nasonex Nasal Spray	“Mometasone furoate will be available in the form of Nasonex Nasal Spray.” NCT05919316 ↗
Known as	SCH 32088	“Dose-Ranging Study of Mometasone Furoate Nasal Spray (SCH 32088) in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (Protocol C95-161)” NCT03879772 ↗ 1 “SCH 32088 mometasone furoate (MF) metered-dose inhaler” NCT01026870 ↗
Known as	SINUVA (mometasone furoate) sinus implant	“SINUVA (mometasone furoate) sinus implant” NCT01732536 ↗ 1 “SINUVA (mometasone furoate) sinus implant” NCT02291549 ↗
Known as	Topison	“Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates” NCT04271007 ↗
Modality	Other / unclassified	“RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy.” NCT00438659 ↗
Route	Intranasal	“Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD” NCT00224523 ↗